Silexion Therapeutics Receives Israeli Approval for Phase 2/3 Pancreatic Cancer Trial

Key Facts

Silexion Therapeutics (SLXN) has received regulatory clearance from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for its lead candidate, SIL204. The study focuses on treating patients with locally advanced pancreatic cancer specifically driven by KRAS mutations, a segment with significant unmet medical needs. This approval marks a critical transition for the company as it enters the advanced clinical development stage for its innovative RNAi-based therapy. SIL204 utilizes a systemic delivery approach designed to target oncogenic drivers that have historically been difficult to treat effectively. The move is expected to bolster investor confidence as the company progresses toward potential commercialization in the high-stakes oncology market. Silexion aims to leverage this milestone to demonstrate the efficacy of its next-generation therapeutic platform in combating aggressive cancer types.